DVA

Business profile & competitive position

DaVita Inc. (DVA) sits in the Healthcare sector under the Medical - Care Facilities industry, and in practical terms it operates one of the largest kidney-dialysis platforms in the United States. As of December 31, 2025, the company ran 2,657 outpatient U.S. dialysis centers serving roughly 200,500 patients, plus an international footprint of 585 centers across 14 countries serving about 94,500 patients. Its business spans outpatient hemodialysis, hospital inpatient dialysis, home-based dialysis, laboratory services, and support for kidney transplantation. U.S. dialysis alone accounted for approximately 86% of consolidated revenues, and the filing notes that nearly all non-hospital dialysis profits came from commercial payors.

The margin profile is informative for anyone looking for a competitive moat. DaVita’s net margin is 6.0%, which is positive but relatively thin. Dialysis is a high-volume, high-fixed-cost service, and the dominant Medicare population is reimbursed at lower rates than commercial insurance. That margin structure points to scale and network density as the real defenses: bigger operators can spread clinic overhead across more treatments and negotiate with commercial insurers from a must-have position. However, ROE is -123.6%, a deeply negative figure. ROE this low is usually a balance-sheet signal rather than proof of no profitability; when shareholders’ equity is small or negative, the standard ROE calculation can swing sharply. Combined with the 6.0% net margin, the message is that DaVita has operating profits but a capital structure that magnifies the denominator in any return-on-equity calculation.

Financial posture

DaVita currently carries an $11.3 billion market capitalization and trades at a P/E ratio of 15.2. Against the broader healthcare facilities space, that multiple reads as fairly moderate, neither deep-value nor premium growth. The 6.0% net margin and -123.6% ROE frame the valuation as a tale of two books: the income statement shows consistent dialysis cash flows, while the equity line reflects years of buybacks, leverage, or accumulated adjustments that leave book value thin.

Beta is 0.87, meaning the stock has historically moved slightly less than the overall market on a percentage basis. At the current snapshot, the price is $176.50, with the 50-day EMA at $201.73 and RSI at 28.3, a level typically interpreted as short-term oversold. Those technical readings say nothing about where price is headed, but they do help explain why recent news coverage has focused on whether the sell-off is overdone.

Strategic priorities & outlook

The company’s most recent 10-K filing lays out three operational priorities. First, DaVita wants to “reimagine” kidney care so it becomes more preventative, better integrated, outcome-focused, lower-cost, and personalized at scale. Second, it is building integrated care capabilities that coordinate treatment across the entire renal continuum, from chronic kidney disease to end-stage kidney disease through kidney transplant. Third, it supports the Comprehensive Kidney Care Contracting (CKCC) model, whose goals are to delay disease progression, promote home dialysis when appropriate, and incentivize transplants.

These priorities point to a strategic shift away from simply running more in-center chairs. Home dialysis and CKCC participation could change the revenue mix over time, but the near-term profit engine remains the outpatient U.S. clinic network and its commercial-payor leverage. The 10-K also highlights quality rankings: DaVita has been an industry leader in CMS’s Quality Incentive Program for the 11 most recently reported years and in the Five-Star Quality Rating System for the 10 most recently reported years. Those metrics matter because reimbursement and program participation increasingly tie payments to outcomes and star ratings.

Macro & geopolitical exposure

As a Medical - Care Facilities operator, DaVita is exposed to the reimbursement and regulatory regimes that dominate U.S. dialysis. Medicare covers most end-stage renal disease patients regardless of age, so federal payment rates, CMS rulemaking, and value-based care experiments such as CKCC directly affect pricing. Congressional or administrative changes to the Medicare ESRD payment bundle can compress or expand margins quickly.

The industry also faces labor-market sensitivity: dialysis clinics require nurses, technicians, dietitians, and social workers, so wage inflation and staffing shortages can pressure operating costs. On the payor side, commercial insurance rates are materially higher than Medicare, which means any federal push toward tighter regulation of commercial dialysis reimbursement would hit the profit pool that currently funds most non-hospital dialysis earnings. International operations add currency translation and foreign regulatory risk, though at roughly 14% or less of the center base the domestic business remains the dominant driver. Supply-chain risks for dialysis machines, concentrates, and needles exist but are generally managed through long-term supplier relationships.

Recent developments

The most recent headlines capture a stock under technical pressure even after an earnings beat. On August 5, 2026, Zacks reported that DaVita stock was down in pre-market despite Q2 earnings beating estimates, with margins down. That same day, Zacks covered the Q2 earnings call and described it as centering on clinical-led volume growth. On August 6, 2026, Zacks asked whether DVA was a great value stock right now, a framing consistent with the P/E of 15.2 and the then-lower price. Then on August 15, 2026, DefenseWorld reported that Bank of America Corp DE cut its holdings in DaVita Inc. Together these items show a market that beat expectations on earnings but punished the shares anyway, likely because margin compression and institutional selling weighed more heavily than the headline beat.

Earnings behavior & post-earnings drift

Over the last eight reported quarters, DaVita has beaten consensus EPS in six of them, a 75% beat rate, with an average earnings surprise of 2.3%. The average 5-day price move in the five trading days after earnings across those quarters is 6.36% to the upside, so at first glance the stock looks like a post-earnings drift candidate.

But the last four quarters tell a more complicated story. On August 4, 2026, DVA reported actual EPS of $4.02 against the market's real expectation of $3.88, a 3.6% positive surprise. The stock fell 17.24% the next day and was down 21.78% over the following five days. That single beat erased the bullish drift signal for anyone trading the headline alone. By contrast, the May 5, 2026 quarter delivered a $2.87 actual versus $2.41 estimate, a 19.1% beat, and produced a 23.46% next-day gain and 27.7% five-day gain. The February 2, 2026 quarter, actual EPS $3.40 versus estimate $3.24 (+4.9%), saw a 21.17% next-day pop and 23.79% five-day drift. The October 29, 2025 miss—actual $2.51 versus estimate $3.17, a -20.8% surprise—produced a -6.17% next-day drop and a -4.27% five-day drift.

The takeaway is that even on beat quarters, the post-earnings drift has not reliably continued in the direction of the surprise. The average 6.36% five-day gain is heavily influenced by the May and February explosions. When the August 2026 beat carried margin concerns, the stock collapsed. For traders, this means the unofficial consensus matters, but so do management commentary, margin trajectory, and guidance outlook. With the next scheduled report on October 28, 2026 after the close and current consensus EPS at $3.58, the setup is one where a beat is not automatically bullish and a miss is not automatically the only bearish outcome.

For a deeper dive into how institutional analysts, hedge funds, and options markets are positioning around DVA ahead of the October 28 report, explore the full institutional verdict on the ticker page.